Inventor · disambiguated record
Ramesh Baliga
Also filed as: BALIGA RAMESH
28 granted patents·26 pending applications·230 citations·filing 2005–2025
97Inventor score
Top patents by PatentIndex Score
54 records- 0198US10975147B2Modified J-chainIGM BIOSCIENCES INC·Filed 2020·Granted Apr 13, 2021·8 cites·28 claims
- 0298US10400038B2Modified J-chainIGM BIOSCIENCES INC·Filed 2015·Granted Sep 3, 2019·21 cites·21 claims
- 0398US9951134B2Modified J-chainIGM BIOSCIENCES INC·Filed 2017·Granted Apr 24, 2018·25 cites·23 claims
- 0497US11542342B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2020·Granted Jan 3, 2023·4 cites·27 claims
- 0597US10618978B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2016·Granted Apr 14, 2020·16 cites·7 claims
- 0696US10954302B2Anti-PD-L1 antibodiesIGM BIOSCIENCES INC·Filed 2017·Granted Mar 23, 2021·10 cites·19 claims
- 0796US10899835B2IgM Fc and J-chain mutations that affect IgM serum half-lifeIGM BIOSCIENCES INC·Filed 2020·Granted Jan 26, 2021·7 cites·28 claims
- 0894US10787520B2Multimeric bispecific binding molecules specific for CD20 and CD3IGM BIOSCIENCES INC·Filed 2016·Granted Sep 29, 2020·13 cites·31 claims
- 0994US9764039B2Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2014·Granted Sep 19, 2017·20 cites·36 claims
- 1093US10604559B2Multi-valent hepatitis B virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Mar 31, 2020·15 cites·18 claims
- 1192US10669347B2Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2017·Granted Jun 2, 2020·5 cites·16 claims
- 1292US9938347B2Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereofIGM BIOSCIENCES AS·Filed 2017·Granted Apr 10, 2018·21 cites·16 claims
- 1392US9738724B2Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2013·Granted Aug 22, 2017·12 cites·35 claims
- 1491US10689449B2Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Jun 23, 2020·12 cites·30 claims
- 1591US9732161B2Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2013·Granted Aug 15, 2017·7 cites·20 claims
- 1690US11535664B2Multi-valent hepatitis B virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Granted Dec 27, 2022·2 cites·19 claims
- 1790US11401337B2Modified human IgM constant regions for modulation of complement-dependent cytolysis effector functionIGM BIOSCIENCES INC·Filed 2018·Granted Aug 2, 2022·6 cites·36 claims
- 1890US7416856B2High sensitivity assay for detection of nucleoside diphosphate productionCYTOKINETICS INC·Filed 2005·Granted Aug 26, 2008·10 cites·21 claims
- 1988US11639389B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2016·Granted May 2, 2023·4 cites·14 claims
- 2088US11555075B2Modified J-chainIGM BIOSCIENCES INC·Filed 2018·Granted Jan 17, 2023·2 cites·46 claims
- 2188US10501558B2Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2017·Granted Dec 10, 2019·3 cites·20 claims
- 2283US11958909B2Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2020·Granted Apr 16, 2024·1 cites·20 claims
- 2383US11578131B2Polynucleotides encoding death domain-containing receptor-5 (DR5) binding moleculesIGM BIOSCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·23 claims
- 2483US2025002604A1Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2581US12486336B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2022·Granted Dec 2, 2025·0 cites·13 claims
- 2681US2023279111A1Modified j-chainIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2780US2024002514A1Anti-pd-l1 antibodiesIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2879US2024124584A1Igm fc and j-chain mutations that affect igm serum half-lifeIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2978US7824880B2High sensitivity assay for detection of nucleoside diphosphate productionCYTOKINETICS INC·Filed 2008·Granted Nov 2, 2010·5 cites·15 claims
- 3078US2023203173A1Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3174US2025304723A1Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 3272US12252552B2Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2019·Granted Mar 18, 2025·0 cites·32 claims
- 3372US2023114070A1Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3468US2021163600A1Anti-pd-l1 antibodiesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3567US2022340676A1Modified human igm constant regions for modulation of complement-dependent cytolysis effector functionIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3667US2022177595A1Multimeric gitr binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3766US2021087273A1IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFEIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3866US2022169751A1Multimeric ox40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3964US2022106399A1Multimeric cd40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4063US2025051473A1Anti-cd38 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4163US2021388098A1Multimeric cd137/4-1bb binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4262US11344626B2Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their useSUTRO BIOPHARMA INC·Filed 2017·Granted May 31, 2022·0 cites·39 claims
- 4359US2021032357A1Cd20 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4456US12473368B2CD25 antibodiesIBIO INC·Filed 2021·Granted Nov 18, 2025·0 cites·12 claims
- 4554US2022372142A1Multimeric antibodies with enhanced selectivity for cells with high target densityIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4653US2023073926A1Highly sialylated multimeric binding moleculesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4752US2022106398A1Anti-gitr antigen-binding domains and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4852US2022306760A1Igm glycovariantsIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4951US2019338040A1Multimeric cd137/4-1bb binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 5051US2019338041A1Multimeric cd40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →